Form D · Biotechnology
Aspira Women's Health Inc.
Austin, TX · CIK 926617
Offering snapshot reported Jul 12, 2024 · SEC filing
- Reported sold
- $1.91M Offering amount: $1.91M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 12, 2024 | Initial | $1,910,250 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-518654
Source: Form D, filed Jul 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stefanie Cavanaugh | Director |
| Celeste Fralick | Director |
| Jannie Herchuk | Director |
| Sandra Milligan | Executive |
| Ellen O'connor Vos | Director |
| Winfred Parnell | Director |
| Nicole Sandford | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12117 Bee Caves Road Building Iii, Suite 100
Austin, TX, 78738
Austin, TX, 78738